Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Amyotrophic Lateral Sclerosis
NCT04326283Phase 2Terminated
- Sponsor
- Genuv
- Start
- Apr 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in amyotrophic lateral sclerosis (ALS), sponsored by Genuv. Started Apr 2020; status: terminated.
02
Drugs
trametinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04326283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326283.